NLRP3 agonists (Bristol-Myers Squibb)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameNLRP3 agonists (Bristol-Myers Squibb)
Drug Alias NameNLRP3 agonist (IFM Therapeutics)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNACHT, LRR and PYD domains-containing protein 3 agonists
TargetsNACHT, LRR and PYD domains-containing protein 3
Therapy Area/IndicationsSolid tumoursNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesIFM Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesBristol-Myers Squibb Company
Inactive CompaniesIFM Therapeutics Inc
Active IndicationsSolid tumours
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A